The Discounted Cash Flow (DCF) valuation of Immunitybio Inc (IBRX) is (58.24) USD. With the latest stock price at 2.57 USD, the upside of Immunitybio Inc based on DCF is -2366.1%.
Based on the latest price of 2.57 USD and our DCF valuation, Immunitybio Inc (IBRX) is a sell. selling IBRX stocks now will result in a potential gain of 2366.1%.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| WACC / Discount Rate | 6.8% - 9.4% | 8.1% |
| Long-term Growth Rate | 3.0% - 5.0% | 4.0% |
| Fair Price | (126.76) - (38.96) | (58.24) |
| Upside | -5032.5% - -1615.9% | -2366.1% |